EPRX Eupraxia Pharmaceuticals, Inc.: Enterprise Value to Sales Volume

Official company branding of Eupraxia Pharmaceuticals, Inc. (EPRX)

Eupraxia Pharmaceuticals (EPRX) holds a competitive advantage through its patented microspheres for the slow release of analgesics. The enterprise value-to-revenue ratio confirms this potential, where 0.00 represents the latest value of this metric. Eupraxia Pharmaceuticals (EPRX) relies on the orthopedic segment by developing anti-inflammatory agents; however, growth is constrained by strict regulatory filters associated with its closed drug delivery platform.

Eupraxia Pharmaceuticals - EPRX EV/Sales Multiple (period 11/23/2025 - 11/20/2026)

Eupraxia Pharmaceuticals, Inc. - analytical breakdowns and key metrics (EPRX)

- current quotes and average value forecast:
- cash balance and cash flow data:
Fundamental company valuation:EPRX - Eupraxia Pharmaceuticals
Finished products of Eupraxia Pharmaceuticals Inc.

The market views Eupraxia Pharmaceuticals (EPRX) as a promising developer of sustained-release drug delivery systems. The EV/Sales metric compares the total enterprise value, adjusted for net debt, against generated revenue. By analyzing the enterprise value-to-revenue trend, investors determine the premium paid for innovative drug delivery technologies. In biopharmaceuticals, this ratio reflects market optimism regarding future sales. The stability of this indicator confirms the company's fundamental resilience.

Direct competitors

HLN: Enterprise Value-to-Revenue Ratio|Kenvue Corp (KVUE) - Enterprise Value-to-Revenue Ratio|Verona Pharma PLC - Business Value to Revenue|Enterprise Value-to-Revenue Ratio Jyong Biotech Ltd|EV/Sales Multiple Ligand Corp|EV/Sales Multiple AMRX|Total Company Value-to-Revenue Ratio Perrigo Company plc|EV/Sales Multiple ALVO (Alvotech Biopharmaceuticals)|LQDA: Company Value to Revenue Ratio|Galapagos N.V. - EV/Sales Multiple|ANIP - EV/Sales Multiple|MNKD: EV/Sales Multiple|amphastar.com (AMPH) - EV/Sales Multiple|PCRX (Pacira Pharmaceuticals) - EV/Sales Multiple|Company Value to Revenue ARS Pharmaceuticals, Inc. (SPRY)|EV/Sales Multiple TBPH|AQST (Aquestive Therapeutics) - Business Value to Revenue|scPharmaceuticals, Inc. - Company Value to Revenue|Business Value to Revenue TECX|tonixpharma.com - EV/Sales Multiple|Business Value to Revenue SXTC (sxtchina.com)|BHST: EV/Sales Multiple|Enterprise Value-to-Revenue Multiple eXoZymes Inc (EXOZ)|ORMP (oramed.com) - EV/Sales Multiple|Company Value to Revenue Ratio ENTX (Entera Bio)|Enterprise Value-to-Revenue Ratio MindWalk (HYFT)|EV/Sales Multiple ABVC BioPharma, Inc. (ABVC)|Enterprise Value-to-Revenue Ratio Cumberland Corp CPIX|QNTM - Company Value to Revenue|FGEN - Enterprise Value-to-Revenue Ratio|TELO - EV/Sales Multiple|Rani Therapeutics Inc (RANI) - Enterprise Value-to-Revenue Ratio|Company Value to Revenue Ratio SNYR|Enterprise Value-to-Revenue Ratio Rallybio Corp|Enterprise Value-to-Revenue Ratio LEXX|EV/Sales Multiple PULM|PTHL: Enterprise Value to Sales Volume|EV/Sales Multiple APM (Aptorum Group Ltd)|LYRA - Company Value to Revenue|Impact BioMedical Inc - EV/Sales Multiple|Enterprise Value to Sales Volume TNFA|YCBD (cbdmd.com) - Company Value to Revenue|painreform.com - Business Value to Revenue|Company Value to Revenue CYTO|Enterprise Value-to-Revenue Ratio LIPO|Enterprise Value-to-Revenue Ratio optinose.com (OPTN)|PIRS (Pieris Pharma) - Business Value to Revenue|Enterprise Value-to-Revenue Ratio Procaps Group S.A. PROC|Total Company Value-to-Revenue Ratio petrospharma.com (PTPI)|QLI - Enterprise Value-to-Revenue Ratio|Business Value to Revenue SLRN (ACELYRIN)|TFF Pharmaceuticals, Inc (TFFP) - Enterprise Value-to-Revenue Ratio